SPBC14C8.15 Antibody

What is SPBC14C8.15 and why are antibodies against it important for research?

SPBC14C8.15 is a gene/protein in Schizosaccharomyces pombe (fission yeast) that plays roles in cellular processes. Antibodies targeting this protein enable researchers to study its expression, localization, and interactions. Similar to how the C8/144B monoclonal antibody was developed to recognize cytokeratin 15 in hair follicle stem cells, SPBC14C8.15 antibodies serve as valuable research tools for investigating specific cellular components . These antibodies allow for immunostaining, immunoprecipitation, and western blotting applications, providing critical insights into protein function, expression patterns, and regulatory mechanisms.

How should SPBC14C8.15 antibody specificity be validated before experimental use?

Antibody validation requires multiple complementary approaches:

• Western blot analysis: Confirm the antibody recognizes a protein of the expected molecular weight in S. pombe lysates. Compare wild-type and SPBC14C8.15 deletion/knockdown strains.

• Immunoprecipitation followed by mass spectrometry: Verify the antibody pulls down SPBC14C8.15 and associated proteins.

• Immunofluorescence microscopy: Compare staining patterns between wild-type cells and SPBC14C8.15 deletion/knockdown strains.

• Neutralization assays: Similar to those used for IL-15 antibodies, these can confirm antibody specificity by demonstrating that the antibody blocks specific protein functions .

• Cross-reactivity testing: Assess potential cross-reactivity with homologous proteins in different species or related proteins within S. pombe.

What are the recommended fixation and permeabilization protocols for immunofluorescence using SPBC14C8.15 antibodies?

For optimal results with SPBC14C8.15 antibodies in immunofluorescence applications:

• Fixation:

  • For most applications: 4% paraformaldehyde in PBS for 15-20 minutes at room temperature

  • Alternative: Methanol fixation (-20°C for 10 minutes) may better preserve certain epitopes

• Permeabilization:

  • 0.1-0.5% Triton X-100 in PBS for 5-10 minutes

  • For membrane proteins: 0.1% saponin may provide gentler permeabilization

• Blocking:

  • 5% normal serum (species different from antibody source) with 0.1% BSA in PBS for 30-60 minutes

Each protocol may require optimization based on specific antibody characteristics, similar to how optimal dilutions must be determined for each application of antibodies like human IL-15 antibodies .

What controls are essential when using SPBC14C8.15 antibodies in western blotting?

Essential controls for western blotting include:

• Positive control: Lysate from cells overexpressing tagged SPBC14C8.15

• Negative control: Lysate from SPBC14C8.15 deletion or knockdown cells

• Loading control: Probing for a housekeeping protein (e.g., tubulin, actin)

• Secondary antibody-only control: To detect non-specific binding

• Pre-immune serum control: For polyclonal antibodies

• Competing peptide control: Pre-incubating the antibody with the immunizing peptide should abolish specific signals

These controls help distinguish specific signals from background and validate antibody performance, similar to the rigorous validation required for other antibodies used in research .

How can computational approaches like RosettaAntibodyDesign (RAbD) be adapted to improve SPBC14C8.15 antibody specificity?

RosettaAntibodyDesign (RAbD) offers promising approaches for optimizing SPBC14C8.15 antibodies:

• Epitope-focused redesign: Starting with an existing SPBC14C8.15 antibody structure (experimental or modeled), RAbD can redesign complementarity-determining regions (CDRs) to enhance specificity for unique epitopes on SPBC14C8.15 .

• Cluster-based optimization: RAbD samples CDR structures from established canonical clusters and optimizes sequences according to cluster-specific amino acid profiles, potentially improving both affinity and specificity .

• Framework adaptation: The flexible-backbone design protocol incorporating cluster-based CDR constraints can be used to adapt antibody frameworks for better stability while maintaining epitope recognition .

• Cross-reactivity reduction: By targeting unique regions of SPBC14C8.15 not shared with homologs, redesigned antibodies can minimize unwanted cross-reactivity.

This computational approach requires:

• Structural information about SPBC14C8.15 (from crystallography or homology modeling)

• Integration with experimental validation

• Iterative refinement cycles to achieve optimal specificity

RAbD has demonstrated success in creating antibodies against proteins like insulin and mycobacterial acyl-carrier protein, suggesting potential for application to SPBC14C8.15 .

What strategies can resolve contradictory results when SPBC14C8.15 antibodies show different subcellular localizations?

Contradictory localization results require systematic troubleshooting:

• Antibody characterization matrix:

  Approach	Purpose	Implementation
  Epitope mapping	Identify if antibodies recognize different domains	Peptide arrays or deletion constructs
  Cell cycle analysis	Determine if localization changes temporally	Synchronized cultures or cell cycle markers
  Fixation comparison	Assess if preparation affects epitope accessibility	Test multiple fixation protocols
  Tagged protein comparison	Provide independent verification	Express SPBC14C8.15 with fluorescent/epitope tags
  Post-translational modification analysis	Identify if modifications affect recognition	Phosphatase treatment, site-directed mutagenesis

• Orthogonal validation: Like the approach used with cytokeratin 15 antibodies , employ multiple techniques (super-resolution microscopy, biochemical fractionation, proximity labeling) to corroborate localization.

• Single-cell analysis: Determine if heterogeneity exists within populations

• Literature reconciliation: Compare with related proteins or orthologs in other organisms

• Bioinformatic prediction: Use algorithm predictions of localization signals as additional evidence

These approaches help distinguish real biological phenomena (multiple localizations, shuttling, splice variants) from technical artifacts.

How can ChIP-seq be optimized when using SPBC14C8.15 antibodies for chromatin studies?

Optimizing ChIP-seq with SPBC14C8.15 antibodies requires addressing several critical parameters:

• Crosslinking optimization:

  • Test both formaldehyde (1-3%, 5-15 minutes) and dual crosslinkers (formaldehyde + DSG/EGS)

  • Optimize based on SPBC14C8.15's interaction type with chromatin (direct or indirect binding)

• Sonication parameters:

  • Target fragment size: 200-500bp

  • Optimize cycles and amplitude to prevent epitope destruction

  • Verify fragmentation efficiency by agarose gel electrophoresis

• Antibody selection criteria:

  • Choose antibodies validated specifically for ChIP applications

  • Test multiple antibodies targeting different SPBC14C8.15 epitopes

  • Consider developing custom antibodies using the RAbD framework for challenging targets

• IP controls:

  • Input chromatin control

  • IgG negative control

  • Positive control (antibody against known chromatin protein)

  • Spike-in normalization with foreign chromatin

• Bioinformatic validation:

  • Motif enrichment analysis of binding sites

  • Correlation with existing transcriptome data

  • Integration with other epigenomic datasets

This methodological framework enables robust ChIP-seq applications, producing reliable genome-wide binding profiles for SPBC14C8.15.

What are the most effective strategies for quantitative comparison of SPBC14C8.15 levels across different experimental conditions?

Quantitative comparison of SPBC14C8.15 requires standardized approaches:

• Western blot quantification:

  • Use near-infrared fluorescent secondary antibodies

  • Include standard curves using recombinant SPBC14C8.15

  • Normalize to multiple housekeeping proteins

  • Analyze with appropriate software for linear dynamic range

• ELISA development:

  • Develop sandwich ELISA using antibodies targeting different SPBC14C8.15 epitopes

  • Create standard curves with purified protein

  • Implement four-parameter logistic regression for quantification

• Mass spectrometry approaches:

  • Targeted proteomics using selected/multiple reaction monitoring (SRM/MRM)

  • Include isotope-labeled peptide standards

  • Focus on proteotypic peptides unique to SPBC14C8.15

• Flow cytometry quantification:

  • Use antibody labeling optimization similar to that employed for IL-15 studies

  • Include calibration beads for standardization

  • Apply compensation for spectral overlap

• Digital calculation matrix:

  Method	Dynamic Range	Sample Requirements	Equipment	Best Application
  Western blot	10-100 fold	10-50 μg protein	Standard lab equipment	Relative changes
  ELISA	1000-10000 fold	1-10 μg protein	Plate reader	Absolute quantification
  Mass Spec	100-1000 fold	50-100 μg protein	Mass spectrometer	Isoform discrimination
  Flow Cytometry	100-1000 fold	10^5-10^6 cells	Flow cytometer	Single-cell analysis

These approaches enable robust quantitative comparisons across different experimental conditions while controlling for technical variables.

How can proximity-dependent labeling methods be combined with SPBC14C8.15 antibodies to discover novel protein interactions?

Integrating proximity labeling with SPBC14C8.15 antibodies enables sophisticated interaction mapping:

• BioID/TurboID approach:

  • Generate SPBC14C8.15-biotin ligase fusion constructs

  • Express in S. pombe under native promoter

  • Biotinylate proximal proteins upon biotin addition

  • Use SPBC14C8.15 antibodies to confirm proper localization and expression

  • Capture biotinylated proteins with streptavidin

  • Identify by mass spectrometry

• APEX2 proximity labeling:

  • Create SPBC14C8.15-APEX2 fusion

  • Verify expression and localization with SPBC14C8.15 antibodies

  • Add biotin-phenol and H₂O₂ for rapid labeling

  • Capture and identify labeled proteins

• Split-BioID approach for conditional interactions:

  • Fuse complementary biotin ligase fragments to SPBC14C8.15 and suspected partners

  • Confirm protein expression with specific antibodies

  • Functional reconstitution occurs only upon protein interaction

• Quantitative interaction mapping:

  • Compare interactomes across conditions (stress, cell cycle, etc.)

  • Use SILAC or TMT labeling for quantitative mass spectrometry

  • Validate key interactions with co-immunoprecipitation using SPBC14C8.15 antibodies

• Data integration framework:

  • Compare proximity labeling results with existing interactome data

  • Apply computational filtering based on cellular localization

  • Construct interaction networks with confidence scores

This methodology combines the specificity of SPBC14C8.15 antibodies for validation with the discovery power of proximity labeling, similar to how antibody design frameworks like RAbD integrate computational and experimental approaches .

What approaches can detect if the SPBC14C8.15 antibody recognizes post-translational modifications that affect function?

Detecting modification-specific recognition requires systematic analysis:

• Phosphorylation assessment:

  • Treat samples with lambda phosphatase before immunoblotting

  • Compare antibody binding before and after treatment

  • Run 2D gel electrophoresis to separate modified forms

  • Use phospho-specific antibodies as controls

• Other modifications (methylation, acetylation, ubiquitination):

  • Treat with specific modification-removing enzymes

  • Generate site-directed mutants at predicted modification sites

  • Compare wild-type and mutant recognition patterns

• Mass spectrometry validation:

  • Immunoprecipitate SPBC14C8.15 with the antibody

  • Analyze by LC-MS/MS to identify modifications present on recognized forms

  • Compare with total SPBC14C8.15 modification profile

• Epitope mapping:

  • Use peptide arrays with and without specific modifications

  • Determine if modifications enhance or inhibit antibody binding

  • Create modification-specific antibody variants using approaches similar to RAbD framework methods

These approaches determine whether the antibody has inadvertent modification specificity, similar to how antibodies have been characterized for specificity in studies of cytokeratin recognition .

How can SPBC14C8.15 antibodies be effectively applied in high-content screening approaches?

SPBC14C8.15 antibodies can be leveraged for high-content screening through:

• Automated immunofluorescence protocols:

  • Optimize staining using robotic liquid handlers

  • Minimize antibody consumption with nanodroplet dispensing

  • Develop multi-parameter staining panels including SPBC14C8.15

  • Implement machine learning for image analysis

• Phenotypic screening setup:

  • Design screens to assess SPBC14C8.15 localization, expression, or modification

  • Create stable cell lines expressing fluorescent reporters as controls

  • Develop Z-factor calculations specific to SPBC14C8.15 readouts

• Multiplexed detection systems:

  • Combine SPBC14C8.15 antibodies with other markers in multiplexed assays

  • Use spectral unmixing for closely related fluorophores

  • Incorporate cyclic immunofluorescence for extended marker panels

• Quality control metrics:

  Parameter	Acceptance Criteria	Troubleshooting Approach
  Signal-to-noise ratio	>5:1	Optimize blocking, antibody concentration
  Coefficient of variation	<15% in control wells	Standardize cell density, fixation time
  Z-factor	>0.5	Refine positive/negative controls
  Edge effects	<10% variation	Use humidity chambers, equilibrate plates
  Day-to-day variation	<20% in controls	Standardize antibody lots, reagent preparation

• Data analysis pipeline:

  • Implement automated image segmentation

  • Extract multiple parameters per cell (intensity, texture, morphology)

  • Apply machine learning for phenotypic classification

  • Integrate with genetic or chemical perturbation data

This approach enables robust high-throughput applications of SPBC14C8.15 antibodies for screening applications, incorporating principles similar to the antibody optimization techniques described for other research antibodies .

What are the optimal conditions for immunoprecipitating SPBC14C8.15 and its binding partners?

Optimizing immunoprecipitation of SPBC14C8.15 requires systematic parameter adjustment:

• Lysis buffer optimization:

  • Test different detergent combinations (CHAPS, NP-40, Triton X-100, Digitonin)

  • Optimize salt concentration (150-500 mM NaCl)

  • Evaluate buffer pH range (7.0-8.0)

  • Include appropriate protease and phosphatase inhibitors

• Antibody coupling strategies:

  • Direct comparison of protein A/G beads vs. covalently coupled antibodies

  • Test different antibody-to-bead ratios (1-10 μg antibody per 50 μl bead slurry)

  • Evaluate pre-clearing strategies to reduce background

• Binding conditions:

  • Optimize incubation time (2h vs. overnight)

  • Compare temperatures (4°C vs. room temperature)

  • Test with and without gentle rotation

• Washing stringency matrix:

  Wash Step	Buffer Composition	Purpose
  Wash 1	Lysis buffer	Remove loosely bound proteins
  Wash 2	Lysis buffer + 100 mM NaCl	Increase stringency
  Wash 3	Lysis buffer + 0.1% detergent	Further reduce background
  Wash 4	PBS or TBS	Remove detergents before elution

• Elution methods:

  • Compare specific peptide elution vs. low pH

  • Evaluate native elution vs. denaturing conditions

  • Test on-bead digestion for mass spectrometry analysis

These optimization steps enable robust immunoprecipitation protocols, similar to the careful optimization required for antibody-based techniques in other systems .

How can SPBC14C8.15 antibodies be effectively used to study protein degradation kinetics?

Studying SPBC14C8.15 degradation kinetics requires specialized approaches:

• Pulse-chase analysis with immunoprecipitation:

  • Metabolically label cells with 35S-methionine/cysteine

  • Chase with unlabeled amino acids

  • Immunoprecipitate SPBC14C8.15 at different timepoints

  • Quantify protein remaining by autoradiography or phosphorimaging

• Cycloheximide chase assays:

  • Inhibit protein synthesis with cycloheximide

  • Collect samples at defined intervals

  • Detect SPBC14C8.15 by western blotting

  • Calculate half-life from degradation curves

• Fluorescence-based degradation assays:

  • Create fluorescent protein-SPBC14C8.15 fusions

  • Validate fusion behavior with SPBC14C8.15 antibodies

  • Monitor degradation using live-cell imaging

  • Calculate degradation parameters from fluorescence decay

• Ubiquitination analysis:

  • Immunoprecipitate SPBC14C8.15 under denaturing conditions

  • Probe for ubiquitin by western blotting

  • Use TUBE (Tandem Ubiquitin Binding Entity) enrichment

  • Identify ubiquitination sites by mass spectrometry

• Proteasome inhibition studies:

  • Treat cells with MG132 or bortezomib

  • Compare SPBC14C8.15 levels before and after treatment

  • Determine ubiquitination status using specific antibodies

  • Assess subcellular localization changes upon inhibition

These approaches provide comprehensive analysis of SPBC14C8.15 stability and degradation mechanisms, using antibodies as essential tools for detection and quantification, similar to how antibodies are used in other protein stability studies .

What are the most effective ways to troubleshoot non-specific binding when using SPBC14C8.15 antibodies?

Addressing non-specific binding requires systematic optimization:

• Blocking optimization:

  • Compare different blocking agents (BSA, milk, normal serum, commercial blockers)

  • Test concentration ranges (1-10%)

  • Evaluate blocking times (30 min - overnight)

  • Consider specialized blockers for problematic samples

• Antibody dilution matrix:

  • Create a dilution series (1:100 - 1:10,000)

  • Test each against positive and negative controls

  • Determine optimal signal-to-noise ratio

  • Similar to the dilution optimization recommended for other research antibodies

• Buffer modification strategies:

  • Add detergent (0.05-0.3% Tween-20 or Triton X-100)

  • Increase salt concentration (150-500 mM NaCl)

  • Add competing proteins (0.1-1% BSA or casein)

  • Test additives (polyethylene glycol, dextran sulfate)

• Pre-adsorption techniques:

  • Pre-incubate antibody with knockout/knockdown lysates

  • Use lysates from related species for cross-reactivity reduction

  • Implement immunodepletion against problematic proteins

• Secondary antibody optimization:

  • Test highly cross-adsorbed secondary antibodies

  • Compare different vendors' products

  • Evaluate fragment-specific secondaries (Fab, F(ab')2)

  • Consider direct conjugation of primary antibody

These approaches systematically reduce non-specific binding while preserving specific SPBC14C8.15 detection, following principles similar to those used in optimizing other research antibodies .

How can super-resolution microscopy be optimized for SPBC14C8.15 antibody-based imaging?

Optimizing super-resolution microscopy with SPBC14C8.15 antibodies requires:

• Sample preparation refinement:

  • Test different fixation protocols (aldehydes vs. organic solvents)

  • Optimize permeabilization to balance antibody access and structure preservation

  • Evaluate refractive index matching solutions

  • Consider expansion microscopy for additional resolution

• Fluorophore selection for specific techniques:

  Super-Resolution Method	Recommended Fluorophores	Considerations
  STED	STAR 580, STAR 635P, ATTO 647N	Photostability, brightness
  STORM/dSTORM	Alexa Fluor 647, Cy5, CF680	Photoswitching properties
  PALM	Conjugate to photoactivatable FPs	Requires genetic engineering
  SIM	Alexa Fluor 488, 555, 647	Brightness, minimal photobleaching

• Antibody labeling optimization:

  • Use Fab fragments for closer epitope proximity

  • Consider nanobodies or camelid antibodies for reduced size

  • Test site-specific labeling strategies

  • Evaluate direct vs. indirect immunofluorescence

• Multicolor imaging strategies:

  • Carefully select non-overlapping fluorophores

  • Implement sequential imaging for challenging combinations

  • Use DNA-PAINT for highly multiplexed imaging

  • Validate colocalization with diffraction-limited controls

• Image acquisition parameters:

  • Optimize laser power to balance photobleaching and signal

  • Adjust pixel size to match resolution (typically 10-20 nm)

  • Determine optimal frame numbers for reconstruction

  • Implement drift correction strategies

These approaches maximize the resolution and specificity of SPBC14C8.15 imaging, building on principles similar to those used in studies of specific protein localization .

What experimental approaches can distinguish between direct and indirect protein interactions with SPBC14C8.15?

Distinguishing direct from indirect interactions requires complementary techniques:

• In vitro binding assays:

  • Purify recombinant SPBC14C8.15 and potential partners

  • Perform pull-down assays with purified components

  • Quantify binding using techniques like surface plasmon resonance

  • Test in the absence of other cellular proteins

• Crosslinking mass spectrometry (XL-MS):

  • Apply protein crosslinkers to living cells

  • Immunoprecipitate SPBC14C8.15 using specific antibodies

  • Identify crosslinked peptides by mass spectrometry

  • Map interaction interfaces at amino acid resolution

• FRET/BRET approaches:

  • Create fluorescent/luminescent protein fusions

  • Measure energy transfer as indicator of proximity

  • Validate expression and functionality with SPBC14C8.15 antibodies

  • Perform controls with non-interacting proteins

• Yeast two-hybrid and derivatives:

  • Test direct interactions in heterologous system

  • Use SPBC14C8.15 as both bait and prey

  • Include controls for auto-activation

  • Validate positive hits with co-immunoprecipitation

• Protein complementation assays:

  • Split-GFP, split-luciferase, or split-ubiquitin systems

  • Reconstitution occurs only with direct interaction

  • Compare signal strength across different protein pairs

  • Validate with antibody-based detection methods

These approaches provide multiple lines of evidence for direct interactions, creating a comprehensive interaction map for SPBC14C8.15, similar to the rigorous validation used in other protein interaction studies .

How should experiments be designed to study SPBC14C8.15 in the context of liquid-liquid phase separation?

Studying SPBC14C8.15 in phase separation contexts requires specialized approaches:

• In vitro phase separation assays:

  • Purify recombinant SPBC14C8.15

  • Test condensate formation under varying conditions

  • Use labeled protein to monitor by fluorescence microscopy

  • Validate protein identity with specific antibodies

• Live-cell imaging approaches:

  • Create fluorescent protein fusions

  • Monitor for puncta formation in different conditions

  • Perform FRAP (Fluorescence Recovery After Photobleaching)

  • Compare localization with immunofluorescence using SPBC14C8.15 antibodies

• Optogenetic control systems:

  • Engineer light-inducible clustering of SPBC14C8.15

  • Monitor consequences of forced condensation

  • Reverse with light-controlled dissociation

  • Validate system components with specific antibodies

• Biochemical isolation of condensates:

  • Fractionate cells under native conditions

  • Detect SPBC14C8.15 distribution by western blotting

  • Identify co-partitioning proteins by mass spectrometry

  • Compare distributions with known phase-separating proteins

• Domain mapping for phase separation:

  • Create truncation mutants of SPBC14C8.15

  • Test each domain's contribution to condensation

  • Identify intrinsically disordered regions

  • Validate expression with domain-specific antibodies

These approaches provide a comprehensive framework for studying SPBC14C8.15's role in phase separation, building on principles used in studies of other phase-separating proteins and requiring specific antibodies for detection and validation .

What are the critical considerations when using patient samples for SPBC14C8.15 antibody-based analyses in translational research?

Translational applications require specific considerations:

• Sample collection and processing standardization:

  • Develop strict SOPs for tissue handling

  • Standardize fixation protocols (timing, temperature, pH)

  • Create processing timelines to preserve epitope integrity

  • Establish quality control metrics for sample adequacy

• Antibody validation in human samples:

  • Validate SPBC14C8.15 antibodies specifically in human tissues

  • Compare multiple antibodies targeting different epitopes

  • Include appropriate positive and negative controls

  • Establish baseline expression in normal tissues

• Ethical and regulatory considerations:

  • Ensure proper informed consent covers antibody-based analyses

  • Address privacy concerns for genetic and protein data

  • Consider return of results policies if clinically relevant

  • Establish biobanking protocols for longitudinal studies

• Clinical correlation workflow:

  • Design robust scoring systems for antibody staining

  • Implement digital pathology for quantitative assessment

  • Correlate with clinical outcomes using appropriate statistics

  • Account for potential confounding variables

• Reproducibility framework:

  • Implement antibody validation strategies from organizations like IBCWG

  • Document detailed methodologies for reproducibility

  • Consider multi-center validation studies

  • Establish reference standards for inter-laboratory comparison

These considerations ensure robust translational applications of SPBC14C8.15 antibodies in human samples, following principles similar to those applied in other translational research using specialized antibodies .